Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts

Biological sex differences in cancer are increasingly acknowledged. Here, we examined these differences in clinicopathological characteristics and survival in microsatellite instability (MSI)-high and microsatellite stable (MSS) gastric cancer (GC). We analysed MSI status by polymerase chain reactio...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2022-09, Vol.173, p.95-104
Main Authors: Quaas, Alexander, Biesma, Hedde D., Wagner, Anna D., Verheij, Marcel, van Berge Henegouwen, Mark I., Schoemig-Markiefka, Birgid, Pamuk, Aylin, Zander, Thomas, Siemanowski, Janna, Sikorska, Karolina, Egthuijsen, Jacqueline M.P., Meershoek-Klein Kranenbarg, Elma M., van de Velde, Cornelis J.H., Buettner, Reinhard, Alakus, Hakan, Cats, Annemieke, Ylstra, Bauke, van Laarhoven, Hanneke W.M., van Grieken, Nicole C.T.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Aged
Cancer
Clinical trials
DNA Mismatch Repair
Female
Females
Gastric cancer
Gastric carcinoma
Gender differences
Humans
Immunohistochemistry
Male
Males
Medical prognosis
Microsatellite Instability
Microsatellite instability (MSI-high)
Mismatch repair
Patients
Polymerase chain reaction
Prognosis
Retrospective Studies
Sex Characteristics
Sex differences
Stability analysis
Stomach Neoplasms - drug therapy
Stomach Neoplasms - genetics
Stomach Neoplasms - surgery
Surgery
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biological sex differences in cancer are increasingly acknowledged. Here, we examined these differences in clinicopathological characteristics and survival in microsatellite instability (MSI)-high and microsatellite stable (MSS) gastric cancer (GC). We analysed MSI status by polymerase chain reaction (PCR) and/or mismatch repair (MMR) status by immunohistochemistry in a pooled analysis of individual patient data from one retrospective cohort from Cologne, and the randomised phase III clinical trials D1/D2 and CRITICS. All patients had resectable adenocarcinoma of the stomach and/or gastro-oesophageal junction. Patients were treated with either surgery only or perioperative chemo(radio)therapy. MSI and/or MMR analyses on 1307 tumours resulted in 1192 (91.2%) MSS and/or MMR proficient (MMRP) [median age, 65 years; 759 males (63.7%); 619 treated with surgery only (51.9%)], and 115 (8.8%) MSI-high [median age, 69 years; 67 males (58.3%); 76 treated with surgery only (66.1%)] GC cases. Males had shorter overall survival (OS) than female MSI-high GC (5-year OS 34.7% vs. 69.7%; hazard ratio (HR) 2.68, 95%CI 1.60 to 4.49; p 
ISSN:0959-8049
1879-0852
1879-0852
DOI:10.1016/j.ejca.2022.06.025